Folate is a water-soluble B-vitamin that humans obtain from their diet. Complex metabolic pathways that involve folate and its derivatives generate essential precursors that sustain cell growth and the antioxidative/methylation capacities of proliferating cells (Fig.1) . Folate metabolism involved the uptake of folate from the environment, followed by its conversion to tetrahydrofolate (THF). One-carbon units from donors such as methionine, serine, glycine, dimethylglycine and sarcosine are transferred to folate carriers, which subsequently pass them on to drive biosynthetic reactions. Methyl-THF (CH 3-THF) donates one-carbon for methylation reactions, methylene THF (CH 2 -THF) is used for the conversion of dUMP to dTMP, and formyl THF (CHO-THF) is used for purine synthesis 5 . A recent important finding has been that the folate pathway is also a major producer of NADPH, a cofactor that powers reductive biosynthesis and redox defences, during the conversion of CH 2 -THF to CHO-THF 6 .
In mammalian cells, folate metabolism is compartmentalised into cytoplasmic and mitochondrial components 5 . It has been estimated through experiments conducted in mouse embryonic fibroblasts (MEF) that approximately 80% of one-carbon units that flow into the methylation cycle originate from the mitochondrial pathway 7 .
Mitochondrial folate metabolism is also a major source of glycine synthesized from 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 serine   2 . MTHFD2 is a metabolic enzyme involved in mitochondrial folate one-carbon metabolism, catalyzing the conversion of CH 2 -THF to CHO-THF (Fig.1 . This study also found that MTHFD2 was not present in normal proliferating cells, but appeared to be specific to proliferating transformed cells. Other studies specifically implicate MTHFD2 in breast cancer:
knockdown of MTHFD2 in breast cancer cell lines has been found to reduce cell viability and increase apoptosis 9 , to impair migration, invasion and metastasis 12 and to increase the expression of cancer stem cell markers 12 . Recent studies have found a significant association between mRNA expression 10, 11 and protein expression of MTHFD2 in large cohorts of breast cancer patients 13 .
Despite the growing interest in MTHFD2 as a potential therapeutic target, the metabolic functions of this enzyme in cancer cells have not been defined. Recent studies have suggested that the benefit to cancer cells of high MTHFD2 expression may be independent of the metabolic functions of the enzyme. An alternative enzyme, MTHFD2L, has been identified to also be able to catalyse the oxidation of CH 2 -THF and is expressed in adult cells 14, 15 . Another recent study has also found that MTHFD2 localized to the nucleus and that over-expression of the enzyme was sufficient to promote proliferation independent of its dehydrogenase activity 16 . 
Materials & Methods

Cell culture
The cell lines examined in this study were obtained from the American Type Culture 
Generation of stable transfected MCF-7 lines
Hush 29mer constructs containing pCMV-shMTHD2 constructs and the transfection reagent Turbofectin 8 were purchased from Origene Technologies (Rockville, MD, USA). MCF-7 cells were transfected with 1 µg of the shRNA constructs or the empty vector. The medium was changed 24 hours after transfection and after a further 24 hours cells were subjected to selection in medium containing G418 (1.0mg/ml, Sigma-Aldrich). After 3 weeks in a selection medium, surviving clones were screened for MTHFD2 expression by qRT-PCR and immunoblotting.
Metabolic requirement growth studies
For the folate depletion experiment, cells were cultured in folate-free RPMI-1640 media supplemented with dialyzed FBS (dFBS, Gibco) or in the same media supplemented with 2.3µM folate (Sigma-Aldrich). Cells were plated at a density of 1000 cells/well in 96-well plates and Cell Counting Kit-8 (Sigma-Aldrich) was used to determine the number of viable cells after 7 days based on the manufacturer's instructions. For the serine and glycine depletion experiment, cells were cultured for 4 days in MEM media (Invitrogen) with depletion of serine (normally 10mM), glycine (normally 10mM) or both serine and glycine. All other NEAA were supplemented at the same concentration as present in MEM NEAA mix (10mM each, Gibco; catalog number 11140050). The number of cells were determined using a Moxi TM z cell counter (Orflo Technologies).
Colony Formation
Anchorage dependent colony formation was performed by plating 1000 cells/well in 30 x 15mm dishes. On day 9, the colonies were fixed using methanol/acetic acid (3:1) and stained using 0.5% crystal violet. The total number of colonies in each dish was counted using the 10x objective of an inverted microscope (Olympus CK2, Japan).
To examine anchorage independent colony formation cells were plated at a density of 10000 cells/well in semi-solid agar (0.4%), plated on top of a layer of solid agar (0.6%). The average number of colonies in a random field was counted on day 13 using the 10x objective of an inverted microscope
ATP level measurement
Cells were plated at a density of 200,000 cells/ml in T25 flasks in normal media and after two days ATP levels were determined by luminescence using the ATP Biolumiescence Assay Kit HS II (Roche, Switzerland).
Quantitative Reverse Transcription PCR
Total RNA was extracted from cells using Trizol (Invitrogen). Reverse transcription was performed using the High capacity cDNA reverse transcription kit (Applied Biosystems). The qRT-PCR was performed using the Taqman Fast advanced master mix and pre-designed taqman probes (Applied Biosystems) in the ABI 7500 RealTime PCR system and relative mRNA levels were calculated using the ∆∆C T method. 
Immunoblotting
Protein was isolated from cells using RIPA buffer (Sigma-Aldrich) and quantified using a BCA assay (Pierce). Monoclonal anti-MTHFD2 (ab56772) was purchased from Abcam and monoclonal anti-beta-Actin (AC-15) antibody was purchased from Sigma-Aldrich. Protein lysates were resolved in 10% Acrylamide gels by SDS-PAGE electrophoresis and the relative intensities were determined using the ImageJ software.
H NMR Spectroscopy
The cell culture media of exponentially growing cells was replenished with MEM media supplemented with dFBS and the media was collected after 24 hours. At the same time, cells were harvested and counted using the trypan blue exclusion method.
The collected cell culture media was centrifuged to remove any cell debris. From the supernatant 550µl were transferred to a fresh tube and 50µl D 2 O containing 0.2% (w/v) 4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA) was added.
High resolution 1 H nuclear magnetic resonance (NMR) spectra were acquired at 14.1 T (600.29 MHz 1 H frequency) using a Bruker AVANCE 600 spectrometer (Bruker Biospin, Rheinstetten, Germany). Spectra were acquired using a Carr-PurcellMeiboom-Gill pulse sequence, and the sum of 128 free induction decays were collected into 64k data points with a spectral width of 12019.230 and 0.3 Hz line broadening.
Gas Chromatography-Mass Spectrometry
Cells were quenched and intracellular metabolites collected by scraping in 750 µL of cold (approx. -70°C) methanol and aqueous metabolites were extracted using a 2:1:3 chloroform:methanol:water extraction method. The aqueous fractions were transferred to silanized GC-MS vials and lyophilized.
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Metabolomic Data Processing
1 H NMR spectra were imported and manipulated in Matlab (Mathworks, Natick, MA, USA) using in-house code for automatic phasing, baseline correction, and referencing chemical shifts to the TSP resonance at δ 0. Metabolites were assigned using Chenomx NMR suite 8.0 (Chenomx Inc., Alberta, Canada) and the Human Metabolome Database. Individual metabolite peaks were integrated and quantified relative to the DSA signal. After peak integration, the intensity for unconditioned media was subtracted, the intensity difference converted to molar change (taking into account proton number) and then the molar change normalised by cell number at the end of the experiment. Metabolite uptake and production were scaled to mean WT dFBS values.
For GC-MS, metabolites were assigned using the Agilent Fiehn Library with the deconvolution program AMDIS. Analysis was carried out based on Retention Index
Data calibrated to fatty-acid methyl ester retention indices from a standard mixture.
Mass spectra for matched metabolites were then compared to the deconvoluted mass 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 spectra to confirm identification. This was followed by analysis using GaVIN as previously described 18 . This involved visual inspection of peak quality (including match to retention time), rejection of metabolites matched by AMDIS in under 80%
of samples, and back-filling of the sample matrix to provide a numerical value for all samples for each metabolite, based on the quantitation ion for each metabolite as taken from the Fiehn library. Calculated integral values obtained from GaVIN were subjected to total area normalization and scaled to mean WT dFBS values.
Results
Generation of MCF-7 cells with stable depletion of MTHFD2
We first determined the levels of the MTHFD2 protein in five cancer cell lines from Fig. 2A,2B ). In agreement with previous reports 9, 11 , the suppression of MTHFD2
affected MCF-7 cell numbers, with clear effects after 4 days of growth (Fig.2C) . No difference was observed in colony formation under adherent conditions in the shMTHFD2 and shCON cells after 72hrs (Suppl. Fig.2A ). No statistical difference was observed in colony formation under non-adherent conditions after 72hrs, although a trend towards decreased number of colonies for shMTHD2 cells was observed (Suppl. Fig.2B ). No effects were observed on ATP levels between the two cell lines, suggesting that suppression of MTHFD2 did not affect energy production under the conditions tested (Suppl. Fig.2C ). 
MTHFD2 suppression renders cells more sensitive to extracellular glycine depletion
In the mitochondria, SHMT2 catalyses the conversion of serine to glycine and generates CH 2 -THF in the process. The conversion of CH 2 -THF to CHO-THF (through the action of MTHFD2) and finally formate (through the action of MTHFD1L) allows the recycling of THF, which can be used for other folatedependent reactions (Fig.1) . To determine whether MTHFD2 suppression affected the conversion of serine to glycine, the intracellular levels of these amino acids were measured in the shMTHFD2 and shCON MCF-7 cells. An increase in intracellular serine together with a decrease in glycine levels was observed in MCF-7 cells following suppression of MTHFD2, consistent with reduced production of glycine from serine (Fig.3A,3B ).
A recent study has suggested that cancer cells rely more on serine than glycine to support growth and metabolism .
To examine how suppression of MTHFD2 affected the dependence of breast cancer cells on exogenous serine and glycine, shMTHFD2 and shCON were cultured in media in which serine, glycine, or both serine and glycine were depleted (Fig.3C ).
Exogenous serine was necessary for the cell growth of MCF-7 cells irrespective of MTHFD2 status. When only glycine was depleted, shCON cells (containing functional MTHFD2) showed no reduction in growth in the presence of exogenous serine. In contrast, shMTHFD2 cells showed decreased proliferation when only glycine was depleted despite the availability of exogenous serine (Fig.3C) . These results suggest that in the absence of MTHFD2 activity, MCF-7 cells become dependent on exogenous glycine and can no longer synthesize sufficient glycine de novo. (Fig.4 ).
Subsequently we examined whether supplementation of the media with formate (2mM), the end product of mitochondrial folate metabolism, could rescue the effect of folate depletion. Our analysis found that formate rescued the cells with wildtype MTHFD2 expression levels, but not the cells with depleted levels of the enzyme (Fig.4) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 production of lactate) together with increased glutaminolysis (increased consumption of glutamine and increased production of glutamate) while also exhibiting reduced mitochondrial metabolism (lower consumption of valine and production of formate).
MTHFD2 suppression renders cells more glycolytic and increases glutamine consumption
To further examine the effects of MTHFD2 suppression on glucose metabolism, we measured intracellular levels of selected glycolytic and TCA metabolites using GC-MS. It was found that MTHFD2 suppression led to decreased intracellular levels of glucose-6-phosphate (G-6-P) and lactate, but not of phosphoenolpyruvate (PEP, Fig.6 ). For TCA metabolites, increased levels of fumarate and malate were detected but citrate, succinate, and α-ketoglutarate were unaffected (Suppl. Fig.4 ).
Discussion
A greater understanding of the metabolic functions of MTHFD2 in breast cancer cells is currently needed to clarify its role in breast cancer and the potential therapeutic benefits of targeting the enzyme. In this study, we identified that the repression of this enzyme affected multiple metabolic pathways in MCF-7 breast cancer cells.
We also found that suppression of MTHFD2 in MCF-7 cells resulted in altered levels of intracellular serine and glycine (Fig.3) , suggesting that the enzyme is required for the functioning of mitochondrial glycine synthesis in these cells. However, further experiments are required to understand the precise contribution of MTHFD2 to this pathway. Notably, shMTHFD2 cells displayed a reliance on exogenous glycine (Fig.3) , consistent with previously reported observations that complete knockout of MTHFD2 rendered mouse embryonic fibroblasts cells glycine auxotrophs (i.e.
completely dependent on exogenous glycine in order to grow) 21 . This study showed for the first time that suppression of MTHFD2 can also produce the same phenotype in human cancer cells. The shMTHFD2 cells examined here could still grow in the absence of glycine (albeit at a slower rate), although it is not clear whether that is due to residual MTHFD2 activity in these cells, the activity of other enzymes such as 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 Fig.3 ). Supplementation of cell culture media with glycine was also unable to rescue cancer cells after RNAi silencing of MTHFD2
11
. The question therefore arises as to why MCF-7 cells with suppressed MTHFD2 are rendered dependent on exogenous glycine. One possibility is that cytoplasmic folate metabolism alone is insufficient to maintain the necessary levels of glycine in MCF-7 cells with suppressed MTHFD2. A second possibility is that glycine is required by the shMTHFD2 cells for the recycling of accumulated CH 2 -THF within the mitochondria. Since CH 2 -THF is unable to flow between the mitochondria and cytoplasm, the only process by which folate trapped in this form can be recycled and used for essential biochemical processes is through the conversion of glycine to serine (Fig.1) . This would be consistent with our observation that the effect of folate depletion on cell growth cannot be rescued by supplementation with formate, the end product of mitochondrial folate metabolism (Fig.4) . However, a major limitation for interpreting and clarifying the link between MTHFD2 repression and the sensitivity to folate depletion is that we did not measure folate metabolites directly in this study, something that needs to be addressed in future work.
A second prominent metabolic phenotype observed in the MCF-7 cells as a consequence of MTHFD2 suppression was an increase in their glycolytic nature.
Serine is a direct ligand and allosteric activator of PKM2 22 , and it was recently reported that suppression of the mitochondrial enzyme SHMT2 upstream of MTHFD2 limits the activity of the PKM2 in glioma cells by decreasing the levels of its metabolic activators 23 . Increased intracellular serine levels due to disruption of mitochondrial glycine synthesis with MTHFD2 suppression may therefore potentially be responsible for the more glycolytic phenotype observed. Another mechanism by which MTHFD2 depletion could affect glucose metabolism in cancer cells is by necessitating a greater diversion of glycolytic intermediates into the pentose phosphate pathway (PPP) for the generation of NADPH. The recent breakthrough paper by Fan et al. 2014 6 reported that folate metabolism, including the mitochondrial branch, is a major source of NADPH, a necessary cofactor for the anabolic synthesis of macromolecules and for protection against oxidative stress 24 . An increased flow of glucose carbon from glucose-6-phosphate to the PPP, the other major NADPH generating pathway, could therefore be a compensatory mechanism. Interestingly a significant decrease in the intracellular levels of glucose-6-phosphate was observed (Fig.6) . One hypothesis that can be tested in future studies is whether cancer cells 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 respond to repression of MTHFD2 by increasing flow of carbons to the PPP thus necessitating an increase in glycolysis.
The increased uptake of glutamine that was observed for shMTHFD2 cells (Fig.5) could also relate to compensatory metabolic reprogramming after suppression of MTHFD2. Glutamine can act to replenish TCA intermediates through its conversion to oxaloacetate, citrate and α-ketoglutarate 25 . Glutaminolysis can also compensate for the reduced production of NADPH by providing a substrate for malic enzyme 26 .
The high expression of MTHFD2 in breast cancer, as well as the association between the levels of this enzyme and poor patient prognosis, demonstrate that altered function of this enzyme confers selective advantages to tumors 2, 10, 12, 13 . However, recent data indicate that MTHFD2 also possesses non-metabolic functions 16 . For example, 
Conclusions
Collectively, the data from this study demonstrate for the first time that the MTHFD2 enzyme contributes to the metabolic reprogramming of breast cancer cells. At least in the MCF-7 cells that were studied here, the more recently discovered MTHFD2L is unable to substitute for suppressed MTHFD2. A more detailed understanding of the role of MTHFD2 in vivo for tumor growth and survival could highlight the conditions under which targeting the enzyme would be therapeutically useful. MTHFD2 is a highly promising target due to its apparently selective expression in cancer cells 11 .
Modelling of the structure of MTHFD2 suggests that it is a potentially druggable target 29 . Additionally, it has been shown in mice that serum glycine and serine can be depleted by diet manipulation 30 . The combination of diet manipulation to deplete glycine with the targeting of MTHFD2 could then be an effective strategy for targeting cancer cells.
Associated Content
Supplementary Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 RPMI media with or without formate supplementation (2mM) compared to cells grown in media containing folate (2.3µM) were determined using the CCK-8 kit.
Culture media was changed every two days until day 7. Data are presented as mean ± SEM of three independent experiments (** p<0.01 *** p<0.001 after a Student's ttest). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 shCON and shMTHFD2 cells. The data are expressed as means ± SD of three replicates. (** p<0.01 after a Student's t-test). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
